Because of increase in the incidence of coronary artery disease (CAD) in younger population with increasing maternal age of pregnancy, the topic of acute myocardial infarction (AMI) during pregnancy has gained importance. Pathophysiologically AMI during pregnancy occurs more frequently due to coronary dissection, which is different in detection and management when compared with the atherosclerotic CAD. Dual antiplatelet drugs that are mandatory following AMI require modification before labor. In this review article, authors discuss in detail about the detection and management of AMI at different stages of pregnancy with the risk stratification and recommendations, including 2018 European Society of Cardiology (ESC) guidelines on "heart diseases during pregnancy." Abstract Keywords ► acute myocardial infarction ► coronary dissection ► dual antiplatelet drugs ► pregnancy Indian J Cardiovasc Dis Women-WINCARS 2018;3:98-107
Introduction Incidence and Prevalence
The incidence of acute myocardial infarction (AMI) during pregnancy is rare, 1 which is approximately 3 to 100 per 100,000 deliveries. 2 However, pregnancy itself will increase the risk by threefold for the development of AMI. 3 As this event to pregnant women increases the maternal mortality (11%) in young age group along with fetal mortality (9%), it requires special attention. 4 Up to 4% of pregnancies may have cardiovascular complications despite no known prior disease. According to Smilowitz 
Period of Pregnancy
Acute myocardial infarction occurrence risk is not confined only during the pregnancy period, but it extends 2 months beyond delivery also. According to Smilowitz et al, AMI most frequently occurred during the postpartum period accounting for 53.5%, followed by during labor (23.7%) and antepartum period (20.6%). 4 As per Elkayam's series also, AMI occurred most frequently in omit either in the third trimester or postpartum. AMI can occur in few cases during the first and second trimesters. Usually, AMI due to normal pregnancy predisposing factors causes myocardial infarction (MI) during the third trimester or peripartum, whereas other comorbidities either related to pregnancy or not contribute to AMI development during the first or third trimester.
Type of Myocardial Infarction
As per the series by Ladner et al, ST-elevation myocardial infarction (STEMI) occurred in 42.4% and rest were non-STelevation myocardial infarction (NSTEMI). 1 A similar incidence was reported by Elkayam et al. 5 Cardiogenic shock occurred in 6.5% of women. Takotsubo's cardiomyopathy was detected in 2.9% of patients. Anterior MI was the most common site (69%) followed by inferior (27%) and lateral MI (4%). 5
Predisposing Factors for Acute Myocardial Infarction during Pregnancy General Factors
• Age: Women who had AMI were older (mean age 33.1 vs. 28.0 years; p < 0.001). 4 Similarly in the series by Elkayam et al, 75% of AMI patients were in > 30 years age group. 5 With increase in maternal age every year, there is a 20% increase in MI risk. • Associated cardiovascular comorbidities: AMI women had more cardiovascular comorbidities such as hypertension, diabetes, thrombophilia, tobacco use, dyslipidemia, known heart failure, anemia, renal insufficiency malignancy, strong family history of migraine headaches, and cocaine usage. 6 With increasing maternal age and increasing coronary artery disease (CAD) in young patients, the number of preexisting CAD patients becoming pregnant is also increasing. Pregnancy may be considered in patients with known CAD in the absence of residual ischemia and clinical signs of left ventricular (LV) dysfunction.
Specific to Pregnancy
There are the factors contributing to the development of AMI during pregnancy-three to four times than nonpregnant age-matched women. 
Pathophysiology of Acute Myocardial Infarction during Pregnancy Sudden Coronary Artery Dissection
Female sex is a risk factor for sudden coronary artery dissection (SCAD). 8 Previous studies on AMI during pregnancy quoted SCAD in 43%, 5 but Smilowitz et al found it in 14.5% of cases. This pathology was more frequent in STEMI than NSTEMI (23.1% vs. 8.2%). 4 SCAD may have single or multivessel involvement. The decreasing order of vessel involvement was the left anterior descending (LAD), left main coronary artery (LMCA), left circumflex artery (LCX), and right coronary artery (RCA). 5 The probable mechanism for SCAD during pregnancy is mentioned in ►Fig. 1. Some of the pregnancy-related SCAD may have background connective tissue disorder or fibromuscular dysplasia. According to the series by Elkayam et al, 5 SCAD occurred in > 40% of patients. SCAD was found as a cause of AMI when AMI occurred during the peripartum period (which means late in pregnancy and early postpartum period). Another interesting finding in the series by Elkayam et al is preponderance of LAD and left main (LM) involvement in CAD cases (►Fig. 2).
Atherosclerotic Disease: Seen in 27% of Cases
Thrombus: A clot without angiographic evidence for atherosclerotic disease was seen in 17% of cases. 5 In addition, during Fig. 1 Pregnancy predisposes to sudden coronary artery dissection-likely mechanism. [24] [25] [26] pregnancy deep vein thrombosis (DVT) with paradoxical embolization to coronaries should also be considered when thrombus is seen angiocardiographically.
Normal Coronary Anatomy: Seen in 11% of Patients
Noniatrogenic coronary spasm was documented in two patients (►Fig. 3). 5 Kawasaki disease in the past was an increasingly recognized cause for CAD in young population. It could be a cause in some pregnant women with AMI.
Management of Acute Myocardial Infarction
The European Society of Cardiology (ESC) has published guidelines on the management of cardiovascular disease during pregnancy. 9 • Diagnosis: AMI during pregnancy is similar to that in nonpregnant women. Important differential diagnoses for AMI in pregnancy include pulmonary embolism, aortic dissection, and preeclampsia. These conditions are to be ruled out before going for specific management of ACS in pregnant women. • Electrocardiogram: Even though new ST depressions, T-wave inversions (in inferior and lateral leads, small Q wave and inverted T wave in lead III, Q wave in lead aVF, inverted T waves in V1, V2, and occasionally V3), and left-axis deviation (15-20 degrees) may be normally seen in pregnancy, 6,10 ST elevations are never seen in normal pregnancy. Therefore, new ST elevation in two consecutive leads suggests AMI in the pregnant woman. • Biomarkers: Increase in biomarkers during pregnancy should be interpreted based on of two parameters: timing of the blood sample and associated pregnancy-related complications. Normally creatine phosphokinase (CPK) is released from the uterus and placenta during labor. 7 Rise in CPK starts immediately after delivery to 24 hours (sometimes up to four times the normal value) and then starts declining later. 11 Therefore, during pregnancy depending only on CPK levels is not wise to diagnose AMI. Similarly, even troponin increase can occur in preeclampsia, gestational hypertension, and peripartum cardiomyopathy. 11 In the absence of aforementioned conditions, an increase in troponin levels may be taken as substantial evidence for AMI diagnosis. • Echocardiogram: New regional wall motion abnormalities (RWMAs) on echocardiogram during pregnancy suggest the coronary event. Increase or decrease in left ventricular mass is not specific for CAD; the increase is known to occur in preeclampsia and multiple gestations. 12 • Treatment: Treatment is also generally the same in pregnancy with consideration of fetal effects.
Medical Management
• Thrombolytic management: Thrombolysis and thrombolytic drugs, according to 2004 ACC/AHA (American College of Cardiology/American Heart Association) guidelines, are relatively contraindicated during pregnancy as these drugs can increase the risk of maternal hemorrhage. Subsequently changed as a relative contraindication. Pregnant women presenting with AMI may have coronary artery dissection causes and hence thrombolysis in these patients is contraindicated as dissection progression may occur. Details are given in ►Table 1. Thrombolysis may be considered only in the centers that do not have percutaneous coronary intervention (PCI) access. • Antiplatelet drugs: Low-dose aspirin (ASA) is safe in pregnancy during the second and third trimesters. ASA is secreted in breast milk in low concentrations without any adverse effect. The side effects of high-dose aspirin are mentioned in ►Fig. 4. There are no randomized studies for dual antiplatelet therapy (DAPT) regimen or for the safety of ticagrelor of prasugrel. Details are mentioned with antiplatelet regimen after PCI (►Table 1).
Invasive Management
As per the series by Smilowitz et al, 25 .1% of patients with AMI during pregnancy underwent coronary revascularization even though 53.1% underwent for invasive management. 4 • Route of invasive procedure: Radial route is preferred as this decreases the radiation dose to the abdomen. During the learning stage, the radial route takes more time to do the procedure, but once that learning curve period is passed, radial route does not take longer time than a femoral route. • Anticoagulation during PCI-unfractionated heparin (UFH): Conventional heparin is preferred for both the mother and fetus. If the patient has allergy to heparin, bivalirudin can be used. 13 During pregnancy, there are increased levels of heparin-binding proteins, factor VIII, and fibrinogen, which can alter the pharmacokinetics of heparin. 14 Therefore, monitoring with activated clotting time 15 is useful for the therapeutic effect of heparin. Heparin does not cross the placenta, so it does not cause fetal complications but can produce uteroplacental junctional bleed. HIT (heparin-induced thrombocytopenia) can happen in 3% of patients. 15 • Low-molecular-weight heparins: There are limited data on this molecule, even though case reports are available. • Radiation precaution during PCI: Shielding the patient's back and abdomen with lead aprons and radial route of PCI minimize fetal radiation exposure. Even though there is much talk about the teratogenic effects of radiation for the fetus during pregnancy, the amount of fetal exposure during PCI (0.02 and 0.1 mSv) is well below the threshold for teratogenicity for any period of pregnancy. 16 A disposable radiation protection sterile drape (Radpad; Worldwide Innovations & Technologies, Inc.) is very lightweight when compared with conventionally used shields, which decreases radiation to an operator to be studied during pregnancy. Other methods such as using simple fluoroscopy, using lower magnification, using low fluoroscopy frame rates, and careful collimation decrease the radiation exposure. • Primary percutaneous coronary angioplasty: ►Fig. 5 shows the flowchart to follow during a case of AMI during pregnancy.
Even though iodinated contrast agent is known to produce fetal congenital hypothyroidism, its incidence is very less. The Contrast Media Safety Committee of the European Fig. 3 Causes of normal coronary anatomy on coronary angiography (CAG) in acute myocardial infarction during pregnancy. 3, 5 Society of Urogenital Radiology and the American College of Radiology recommends only routine thyroid testing at the time of birth. 17 Stent type: Bare-metal stent (BMS) is preferred over drug-eluting stent (DES) in patients undergoing primary PCI for AMI during pregnancy, especially if an event occurs in the third trimester. Four weeks of DAPT is safe with BMS PCI, to interrupt the DAPT before delivery. 18 • Management drug regimen subsequently: ►Table 1 gives the details of different drugs and its indications, which are essential for post-PCI. • DAPT interruption during delivery: ►Fig. 6 shows the algorithm for interruption of DAPT during pregnancy. 19 Even in a case report, 13 the antiplatelet regimen was not interrupted during labor and delivery.
Surgical Management
There are limited data on the surgical management of the AMI during pregnancy in the literature. 20 In the series by Elkayam et al, coronary artery bypass grafting (CABG) was done in 30 patients, out of whom 23 had SCAD. CABG has done in 11 patients during pregnancy, rest of cases in the postpartum period. There was no maternal mortality, and only one fetal loss was reported. 5 There is a suggestion that lower risk of fetal loss with contemporary surgery, which was substantiated by Immer et al. 21 
Anesthesia Considerations
Neuraxial (spinal, epidural, combined spinal-epidural) analgesia is the preferred modality for cesarean delivery for these patients with AMI complications. If required, epidural analgesia can be converted to epidural anesthesia. The major problem of neuroaxial anesthesia is hypotension, which can be minimized with low-dose local anesthetic technique and proper intravenous (IV) fluid management. Other important concern with this anesthesia is the epidural hematoma in patients who received DAPT. The algorithm for DAPT discontinuation is discussed subsequently.
Management during Labor and Delivery
In these patients with AMI complications, the treating physician should be individualized the patient who is to undergo vaginal or cesarean delivery (►Fig. 7). 13, 22, 23 
Complications Maternal
All mechanical, electrical, and myocardial loss complications occurring during AMI were known to occur in a pregnant patient with AMI with increasing incidence and mortality. As per the series by Elkayam et al, complications of heart failure or cardiogenic shock occurred in 38% of patients, ventricular arrhythmias in 12%, recurrent angina or AMI in 20%, and maternal mortality in 7%. 5 No complications were related to the drugs even with thrombolytic or GP2b/3a inhibitors in this series. 5 The drugs that are safe and contraindicated from these conditions are mentioned in ►Tables 1-3.
Intra-aortic balloon pump (IABP) can also be used safely during pregnancy if required for cardiogenic shock, but the patient should be in the left lateral position. 18 
Fetal
Most fetal deaths were associated with maternal mortality. There is decreasing trend from 1996 (20%), 2008 (12%) to 2011 (7%).
Follow-up and Prognosis
As per the series by Smilowitz et al, the in-hospital mortality was 40-fold higher in patients with AMI than those without AMI during pregnancy (adjusted OR: 39.9; 95% CI: 23.3-68.4; p < 0.001), occurring at a rate of 4.5%. Even though there is a substantial improvement in the management of AMI patients in general, it is not translated into the pregnant female population.
• Exercise test-for risk stratification of post-MI: At maximal maternal exercise, there may be fetal distress. Therefore, the submaximal protocol for fetal monitoring is advisable. • Risk of subsequent pregnancies-SCAD: It recurred in 17% of patients in a median follow-up of 47 months. 24 Therefore, subsequent pregnancy may not advisable. Roth 3, 5 compared the different studies from 1922 to 2011. which is divided into three periods: 1922 to 1995 (period 1), 1995 to 2005 (period 2), and 2006 to 2011 (period 3). The mean age was > 30 years with multiparous status, hypertension, and diabetes as risk factors in all these periods except that family history of AMI is increased in periods 2 and 3. Comparing the coronary anatomy after AMI during pregnancy, stenosis was greater in period 1 (43% vs. 27%) than in period 3, and coronary dissection was reported to be higher in period 3 (16% vs. 43%) than in period 1. Normal coronary anatomy was more frequent in period 1 (29% vs. 11%) than period 3. There is decreasing tendency in maternal (20, 11 , and 7%) and fetal (12, 9, and 5%) mortality in study periods 1, 2, and 3, respectively.
Changing Pattern of Acute Myocardial Infarction during Pregnancy over a Century
Smilowitz et al reported similar changes in the 2002 to 2012 period of AMI complicated pregnancy in the U.S. population. 4
Conclusion
Acute myocardial infarction during pregnancy is different from that in the age-matched nonpregnant woman, as both maternal and fetal mortalities are high. ESC 2018 guidelines on heart disease in pregnancy covered a few components of AMI during pregnancy; for example, testing tropin measurement in a pregnant patient with chest pain and primary PCI for STEMI during pregnancy are class 1 indications and invasive strategy for high-risk NSTEMI and conservative strategy for low-risk NSTEMI are class IIa indications. 
